Aurobindo Pharma informed exchanges that the new injectable facility of Eugia Steriles Private Limited (a 100% subsidiary of Eugia Pharma Specialities Limited and a stepdown subsidiary of the Company), located at Parawada Mandal, Anakapalli District, Andhra Pradesh, which was inspected by the US FDA from March 28, 2024 to April 05, 2024, has gotten its first product approval from the US FDA for Lidocaine Hydrochloride Injection, USP, 1% (10 mg/mL) and 2% (20 mg/mL).
In the exchange filing, the company also shared, “The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility.”
In the meantime, as of 11:45 am, Aurobindo Pharma shares were trading 1.01% higher at Rs 1,533.80 on the NSE.
